A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis | MicrobiomeTrials
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-15Est. Completion: 2030-03-31
Enrollment target: 100 participants
Locations
University of South Florida, Tampa, Florida, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
NYU Langone Health, New York, New York, United States
Mater Hospital Brisbane, South Brisbane, Queensland, Australia
Royal Children's Hospital, Parkville, Victoria, Australia
Perth Children's Hospital, Nedlands, Western Australia, Australia
Children's Hospital ZheJiang University School of Medicine, Hangzhou, Zhejiang, China
Emmed Research, Pretoria, South Africa
National Taiwan University Hospital, Taipei, Taiwan
Chulalongkorn University, Bangkok, Thailand
Siriraj Hospital, Bangkok, Thailand
Ramathibodi Hospital, Bangkok, Thailand
Birmingham Children's Hospital, Birmingham, United Kingdom
Addenbrooke's Hospital, Cambridge, United Kingdom
Sheffield Childrens Hospital, Sheffield, United Kingdom
Other microbiome trials you might be interested in